Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identification of prognostic factors

Meletios A Dimopoulos; D. Weber; Kay Delasalle; Michael J. Keating; Raymond Alexanian

doi:10.1093/oxfordjournals.annonc.a059040

Related publications

Article1993

Treatment of Waldenstrom Macroglobulinemia with 2-Chlorodeoxyadenosine

Meletios A Dimopoulos

Article1994

Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.

Meletios A Dimopoulos, H. Kantarjian, D. Weber, S O'brien, E Estey, Kay Delasalle, Esther Rose, Fernando Cabanillas, M Keating, Raymond Alexanian

Article1994

Primary Therapy of Waldenstriim's Macroglobulinemia With 2-Chlorodeoxyadenosine

Meletios A Dimopoulos, Hagop M. Kantarjian, Donna Weber, Susan O’Brien, Elihu H. Estey, Kay Delasalle, Esther Rose, Fernando Cabanillas, Michael M. Keating, Raymond Alexanian

Article2004

Treatment of Waldenstrom's Macroglobulinemia with Rituximab: Prognostic Factors for Response and Progression

Meletios A Dimopoulos, Raymond Alexanian, Dimitra Gika, Athanasios K. Anagnostopoulos, Constantinos Zervas, Athanassios Zomas, Marie Christine Kyrtsonis, Nicolaos Anagnostopoulos, Gerassimos A. Pangalis, Donna M. Weber

Article2003

Survival and prognostic factors after initiation of treatment in Waldenstrom’s macroglobulinemia

Meletios A Dimopoulos, George Hamilos, Konstantinos Zervas, Argiris Symeonidis, G. Kouvatseas, Paraskevi Roussou, Dimitra Gika, Efthymios Karmiris, Konstantinos L. Bourantas, Athanasios Zomas, C. Mitsouli, Irini Xilouri, E. Vervessou, K. Matsis, Nicolaos Anagnostopoulos, T. Economopoulos